semaglutide cardiovascular news today Insights into research: Mechanisms, trials, and frontiers Semaglutide and Cardiovascular Outcomes in

This decline contributes to age-related changes in body composition, energy, sleep quality, and recovery capacity

OctoberDecember 2025: imlunestrant Imlunestrant, a next-generation, brain-penetrant, oral selective estrogen receptor degrader (SERD) by Eli Lilly, is awaiting FDA approval for patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer

GLP-1RAs exert pleiotropic effects that extend well beyond their initial use in glycemic management [8]

The complex stabilizes the copper ion where the cells can easily recognize and utilize

Improved Muscle & Bone Health: Supports lean muscle growth, enhances bone density, and aids in physical recovery